Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Art of Memory for Cognitive Enhancement in the Monza Brain Health Service

NCT07479914 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-11-24
Last updated
2026-03-18

Condition(s) studied

Subjective Cognitive Decline (SCD)Alzheimer's DiseaseCognitive Enhancement

Investigational drug(s) / intervention(s)

Art of memory classesGeneral information on art of memory

Art of memory classes: The intervention will consist of: * two in-person and two online group sessions to learn basic and advanced memory techniques, taught by experienced memory athletes (Vanni de Luca, Andrea Muzii and Alessandro de Concini) * dedicated online video materials * self-paced exercises on the memoryleague.com website for about 20 minutes per day

General information on art of memory: The control group will receive general information about memory techniques but no structured training or platform access

Study summary

The goal of this pilot interventional clinical trial (non-drug study) is to learn whether memory techniques (mnemonics) can improve cognitive performance in adults over 50 years old with subjective cognitive decline who are followed at the Brain Health Service of Monza. The study will also evaluate the feasibility of this intervention and explore which biological or clinical factors may influence its effects.

The main questions it aims to answer are:

* Do memory techniques improve overall cognitive performance, measured by a composite score from a neuropsychological test battery, after 6 months?
* Are any cognitive benefits maintained over time (up to 9 months)?
* Do biomarkers (such as blood p-tau217 levels, APOE genotype, or brain atrophy on MRI) influence the response to memory training?
* Do memory techniques improve subjective cognitive complaints and performance on sensitive memory and cognitive-motor tests?

Researchers will compare a memory training group to a control group receiving information only to see whether structured mnemonic training leads to greater improvement in cognitive outcomes.

Participants will be randomly assigned to either the memory training group or the control group. Both groups will undergo complete cognitive assessments at baseline, 6 months, and 9 months.

If assigned to the training group, participants will attend two in-person group sessions to learn basic and advanced memory techniques, participate in two additional online group meetings, access online video materials, and practice memory exercises on a dedicated online platform for about 20 minutes per day.

If assigned to the control group, participants will receive general information about memory techniques but no structured training or platform access.

A total of 80 participants (40 per group) will be enrolled. This pilot study will help estimate the size of the effect and determine whether a larger future study is feasible.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Subjective Cognitive Decline (SCD) according to Jessen et al., 2014 criteria * Evaluation at the Brain Health Service (BHS) of Monza * Prior brain MRI performed at Fondazione IRCCS San Gerardo dei Tintori * Prior blood sampling for measurement of biomarkers of cerebral amyloidosis * Age \> 50 years * Adequate digital literacy (ability to access websites and participate in video calls) * Ability and willingness to provide written informed consent before study participation Exclusion Criteria: * Severe visual and/or hearing impairment interfering with participation * Inability to participate in online training activities or attend in-person group sessions * Enrollment in another interventional study with an expected effect on cognition * Refusal or withdrawal of consent to participate

Primary outcome measure(s)

  • Change from baseline to 6 months in composite neuropsychological test battery (NTB) z-score (range: - infinity, infinity; higher scores mean better outcomes) — Baseline to 6 months
    Difference between the active mnemonic training group and the control group in the longitudinal change of the composite z-score derived from a standardized neuropsychological test battery (NTB). The composite score reflects global cognitive performance.

Trial sites (1)

FacilityCityRegionStatus
Fondazione IRCCS San Gerardo dei Tintori Monza Lombardy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07479914 on ClinicalTrials.gov ↗ ← All trials in Italy